Table 3.

Patient diagnosis and carfilzomib dose cohorts (dose escalation)

Dose cohort
1.2 mg/m22.4 mg/m24.0 mg/m26.0 mg/m28.4 mg/m211.0 mg/m215.0 mg/m220.0 mg/m227.0 mg/m2All patients
n = 3n = 3n = 4n = 3n = 3n = 4n = 3n = 8n = 6)N = 37
Dose escalation
Diagnosis
 MM03021226521
 NHL30312212115
 HL0010000001
Cyclesa per patient
 Mean2.05.74.54.74.33.05.72.05.53.9
 Range1.0–4.01.0–14.00.0–14.01.0–12.02.0–9.02.0–6.01.0–14.00.0–7.00.0–10.00.0–14.0
Cumulative dose, mg/m2
 Median14270202330339253595285820132
 Range7–2914–76616–69230–91284–833132–57275–153040–92054–15667–1566
Dose cohort
N = 11 patients20/27 mg/m2 (n = 7)20/27 mg/m2 + Dex (n = 4)
Dose expansion
Diagnosis
 MM (n = 7)34
 NHL (n = 2)20
 Waldenström's macroglobulinemia (n = 2)20
Cycles per patient
 Mean3.94.0
 Range1.0–12.01.0–12.0
Cumulative dose, mg/m2
 Median282168
 Range80–1,90370–1848

Abbreviations: CFZ, carfilzomib; HL, Hodgkin lymphoma; MM, multiple myeloma; NHL, non–Hodgkin lymphoma; WM, Waldenström's macroglobulinemia.

  • aIncludes patients with multiple dose escalations to higher dose levels.